The impact of myo-inositol on glycoregulation and lipid profile
Abstract
Myo-inositol has attracted attention due to its potential as a therapeutic agent in the treatment of metabolic disorders, particularly diabetes mellitus (DM) and lipid profile disorders. This study investigates the role of myo-inositol in the regulation of glucose metabolism, insulin sensitivity, and lipid profile, with a special focus on its impact on type 2 diabetes and associated lipid disorders. Myo-inositol plays a key role in insulin signaling by regulating insulin action in target tissues, enhancing glucose uptake, and reducing insulin resistance. Clinical studies show that myo-inositol supplementation can lead to significant improvements in glycemic control, including reduced fasting glucose levels and HbA1c, and affects the lipid profile by lowering total cholesterol, LDL, and triglycerides, while increasing HDL levels. Furthermore, myo-inositol shows potential in addressing diabetes-related complications, including diabetic nephropathy and oxidative stress. These findings suggest potential of myo-inositol as an adjunctive therapy in the treatment of diabetes and lipid disorders. However, further clinical research with larger sample sizes is needed to fully understand the long-term effects and safety in patients with diabetes. This review highlights the need for further studies to optimize the therapeutic applications of myo-inositol in metabolic disorders.
References
Michell RH. Inositol derivatives: Evolution and functions. Nat Rev Mol Cell Biol. 2008;9(2):151–161. doi: 10.1038/nrm2336.
Chauhan N, Jogpal V. Investigating the role of inositol: Myo-inositol and D-chiroinositol in diabetes: A review. Agri Articles. 2021;10.18805/ag.R-2706.
Caputo M, Bona E, Leone I, et al. Inositols and metabolic disorders: From farm to bedside. J Tradit Complement Med. 2020;10(3):252-259.
Bizzarri M, Carlomagno G. Inositol: History of an effective therapy for Polycystic Ovary Syndrome. Eur Rev Med Pharmacol Sci. 2014;18(13):1896–1903.
Zarezadeh M, Dehghani A, Faghfouri AH, Radkhah N, Kermanshahi MN, Kalajahi FH, Mohammadzadeh Honarvar N, Ghoreishi Z, Ostadrahimi A, Ebrahimi Mamaghani M. Inositol supplementation and body mass index: A systematic review and meta-analysis of randomized clinical trials. Obes Sci Pract. 2021;7(5):569-579. doi: 10.1002/osp4.56.
DiNicolantonio JJ, O'Keefe J. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9:e001989. doi: 10.1136/openhrt-2022-001989.
Condorelli RA, Calogero AE, La Vignera S. Myo-inositol: Does it improve sperm mitochondrial function and sperm motility? Urologia. 2012;79(Suppl 19):24–6. doi: 10.5301/UROLIA.2012.10414.
Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811–1827. doi: 10.1016/j.biochi.2013.05.009.
Maurizi AR, Suraci C, D'Onofrio L, Casagrande V, Barchetta I, Cavallo MG, et al. A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol. 2017;54(4):361-365. doi: 10.1007/s00592-016-0954-x.
Stanković V, Jović D, Mitić S, Mitić S. Myo-Inositol in Type 1 Diabetes - Case Report. In: Book of Abstracts, 15th International Congress on Nutrition: Food, Nutrition, and Health within the Framework of Sustainable Development; 2024 Nov 20-22; Belgrade, Serbia. Serbian Nutrition Society; 2024. p. 120.
Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997;7(2):147–55. doi: 10.1016/S0924-977X(96)00029-9.
Carlomagno G, Unfer V. Inositol safety: Clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931–36.
Baldassarre MPA, Di Tomo P, Centorame G, Pandolfi A, Di Pietro N, Consoli A, Formoso G. Myo-inositol reduces inflammation and oxidative stress in human endothelial cells exposed in vivo to chronic hyperglycemia. Nutrients. 2021;13(7):2210. doi: 10.3390/nu13072210.
Bevilacqua A, Bizzarri M. Inositols in insulin signaling and glucose metabolism. Internet J Endocrinol. 2018;2018:1968450.
Chukwuma CI, Ibrahim MA, Islam MS. Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: A dual approach study. J Physiol Biochem. 2016;72:791–801.
Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metabol Toxicol. 2016;12(10):1181-1196.
Matarrelli B, Vitacolonna E, D'Angelo M, et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: A randomized controlled trial. J Matern Fetal Neonatal Med. 2013;26:967–72.
Santamaria A, Alibrandi A, Di Benedetto A, et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: A secondary analysis from 3 RCTs. Am J Obstet Gynecol. 2018;219(3):300.e1-e300.e6.
Giordano D, Corrado F, Santamaria A, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: A perspective, randomized, placebo-controlled study. Menopause. 2011;18:102–4.
Miñambres I, Cuixart G, Gonçalves A, Corcoy R. Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019;38(3):1146-1152.
Tabrizi R, Ostadmohammadi V, Lankarani KB, et al. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17:123.
Fatima K, Jamil Z, Faheem S, Adnan A, Javaid SS, Naeem H, Mohiuddin N, Sajid A, Ochani S. Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: A meta-analysis. Ir J Med Sci. 2023;192(6):2801-2808. doi: 10.1007/s11845-023-03388-5.
Shokrpour M, Foroozanfard F, Ebrahimi F, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: A randomized controlled clinical trial. Gynecol Endocrinol. 2019;35:406–411.
Genazzani AD, Prati A, Simoncini T, Napolitano A. Modulatory role of D-chiroinositol and alpha lipoic acid combination on hormonal and metabolic parameters of overweight/obese PCOS patients. Eur Gynecol Obstet. 2019;1(1):29-33.
Tabrizi R, Ostadmohammadi V, Lankarani KB, et al. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17:123.
